Clairity, Inc.

Name: Clairity, Inc.
Brand: Clairity, Inc.

AI Native

Fulfilling the promise of precision medicine through the power of AI

Est 2020|Valuation $137M|Raised $53.8M|2 Ref Customers

LinkedIn 3K|Web traffic 3K|FTEs 15|HQ Boston, Massachusetts, US

Published Aug 14, 2026

01Common complaints

1. If you need transparent pricing and immediate ROI certainty - Clairity’s pricing is not public, and reimbursement is reportedly not yet established. If you need a clearly reimbursed pathway now, workflow-first risk management using established models (or existing reimbursed diagnostic pathways) may be more pragmatic. 2. If your program cannot operationalize risk findings - If your system lacks MRI slots, genetics services, navigation staffing, or agreed clinical protocols, adding a new risk signal may increase workload without improving outcomes. 3. If your imaging infrastructure is mismatched - If your mammography devices/workflows rely on image types the product does not support (e.g., synthetic 2D) or if integration constraints are tight, consider alternatives or delay. 4. If you want mature, review-validated enterprise software - There is minimal presence on standard B2B review platforms. Buyers who heavily weight extensive peer reviews may prefer more established vendors with abundant third-party feedback.

Deal disqualifiers / poor fit

Centers without sufficient capacity for downstream follow-up (advanced imaging or genetics) may create a bottleneck.
Sites using mammography workflows heavily dependent on synthetic 2D as the primary standard view, given Clairity’s documented limitation.
Organizations requiring published security certifications as gating criteria unless Clairity can provide them under NDA.

Vendor-acknowledged / publicly documented constraints

Image type support limitations: Clairity notes it analyzes FFDM / directly acquired 2D from specific systems and does not analyze synthetic 2D images (important for tomosynthesis-heavy workflows).

Roadmap / future products mentioned publicly

Press materials mention development of:
- Clairity Breast 3D
- Clairity Heart (cardiovascular risk prediction from routine imaging)

Scale limitations

Not publicly documented (throughput, latency, max studies/day, downtime SLAs, etc.). Buyers should request performance SLAs and reference architectures.

Security/compliance gaps

As noted, security certifications not publicly documented in accessible sources.

02Why they buy

Differentiators supported by available evidence

FDA De Novo authorization for an image-based AI platform intended to provide 5-year breast cancer risk prediction from screening mammography.
Vendor states the model derives additional imaging features beyond standard clinical inputs and emphasizes goals related to equitable risk assessment.

Where competitors may have advantages

Broader suite maturity: iCAD and other established imaging AI vendors may offer more mature deployment playbooks, broader device coverage, and packaged offerings.
Workflow depth: MagView and similar platforms may provide deeper operational tooling for letters, tracking, compliance, and risk clinic operations.

03Field reports

Key limitation: scarce review-platform coverage

Clairity Breast is a regulated medical device software product with early commercialization. It does not appear to have meaningful presence on common review platforms (G2, TrustRadius, Capterra) as of March 10, 2026.

Gartner Peer Insights: access attempt was blocked by robots.txt during collection; no accessible Clairity listing was retrieved.
G2 / TrustRadius / Capterra: searches did not surface a Clairity Breast listing with end-user reviews.

What we can use instead

Because formal review coverage is missing, feedback is currently inferred mostly from:

Early deployment news coverage
Vendor statements
Regulatory documents describing intended use and limitations
Community discussion is sparse and often not about the medical product

Vendor/press statements (neutral summary)

Vendor and partner communications describe applying predictive analytics to screening mammography and note early clinical rollout milestones.
Local reporting notes the product may identify risk not captured by genetic testing, while also reporting limited or unclear insurance coverage.

Negative/critical signals (where available)

Because validated end-user review quotes are not available, the main criticisms are structural adoption risks surfaced in reporting and regulatory framing: - Coverage and payment uncertainty: reporting indicates the technology is not widely covered by insurance yet, which is a practical adoption barrier (providers may hesitate without reimbursement clarity; patients may face out-of-pocket costs). - Intended-use limits: FDA documentation emphasizes it’s not a diagnostic/detection tool; organizations must avoid over-relying on the score in ways the device is not authorized for.

Why customers may choose Clairity vs alternatives (inferred)

A multi-year prediction horizon based on mammography alone (differentiator vs alternatives oriented to shorter horizons or requiring non-imaging data).
FDA De Novo authorization for this indication (provides regulatory context compared with non-cleared academic tools).
Workflow integration via the MagView ecosystem may reduce integration work for centers using that vendor.

Why some may not purchase / may delay (inferred)

Budget/reimbursement concerns.
Need for strong clinical governance and patient communication protocols.
Concerns about bias, generalizability, and medico-legal exposure if risk scores change management decisions.

Early deployment milestone (Beth Israel Deaconess Medical Center)

News coverage reported a rollout at Beth Israel Deaconess Medical Center in early 2026, describing the tool and reiterating insurance coverage is not in place.

Critical evaluation:

This is not a quantified ROI case study (no published metrics such as increased detection rates, stage shift, or reduced interval cancers). It is primarily a deployment announcement.

Vendor-published clinical validation narrative

- Company materials and clinical summaries describe training/validation cohorts (e.g., very large mammography datasets used in development and large U.S. validation cohorts with multi-year outcomes). Critical evaluation: - These are largely vendor-reported summaries. Buyers should request: - full peer-reviewed validation publications - site-level subgroup performance (race/ethnicity, age, density, equipment vendors) - calibration plots and decision-curve analyses - clinical utility evidence (changes in management and outcomes)

04Best fit

Best-fit organizations

- Health systems / imaging networks with: - established breast imaging volume (screening mammography at scale) - active high-risk screening programs (MRI capacity, genetics referral pathways) - robust radiology IT integration capabilities Indicative size range (practical, not strict): - Multi-site imaging groups or hospitals with high annual screening volumes where predictive risk stratification could materially reshape downstream pathways.

Strongest roles/personas

Decision makers: VP women’s health, radiology chair, breast imaging director, population health leadership, CFO/finance (reimbursement).
End users: breast radiologists, nurse navigators, genetic counselors, scheduling teams.

Key pain points addressed

Under-identification of elevated risk when risk is not genetic and when clinical risk model inputs are incomplete.
Desire to move from a uniform annual screening approach to risk-stratified pathways.

05The pitch

What the product does (objective value proposition)

Clairity, Inc. offers Clairity Breast (FDA De Novo authorized under the device name Allix5), an image-based AI prognostic/risk-prediction software that generates a 5-year breast cancer risk probability using a patient’s existing screening mammogram (i.e., a predictive risk assessment rather than detection/diagnosis). The product is intended to identify women who may be eligible for earlier or more intensive screening and prevention pathways beyond traditional risk factors such as family history or breast density. Key product claims and scope (per vendor and FDA materials): - Produces a calibrated 5-year risk score from screening mammography images; explicitly not intended to diagnose or detect breast cancer. - The healthcare-provider page indicates modality/device constraints (e.g., supports FFDM / directly acquired 2D and does not analyze synthetic 2D images; mentions compatibility with Hologic Lorad Selenia and Selenia Dimensions systems).

Target market and positioning

Primary buyers/users appear to be: - U.S. health systems, breast imaging centers, radiology groups (especially those operating risk clinics / high-risk screening programs). - Stakeholders: radiologists, breast imagers, breast surgeons, high-risk program coordinators, and women’s health program leadership. Vendor communications describe the product as a predictive capability integrated with routine mammography workflows and as a tool intended to broaden identification of elevated risk beyond genetics-based approaches.

Get a comprehensive analysis of Clairity, Inc. including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Aug 14, 2026

01Common complaints

If you need transparent pricing and immediate ROI certainty
- Clairity’s pricing is not public, and reimbursement is reportedly not yet established. If you need a clearly reimbursed pathway now, workflow-first risk management using established models (or existing reimbursed diagnostic pathways) may be more pragmatic.
If your program cannot operationalize risk findings
- If your system lacks MRI slots, genetics services, navigation staffing, or agreed clinical protocols, adding a new risk signal may increase workload without improving outcomes.
If your imaging infrastructure is mismatched
- If your mammography devices/workflows rely on image types the product does not support (e.g., synthetic 2D) or if integration constraints are tight, consider alternatives or delay.
If you want mature, review-validated enterprise software
- There is minimal presence on standard B2B review platforms. Buyers who heavily weight extensive peer reviews may prefer more established vendors with abundant third-party feedback.

Deal disqualifiers / poor fit

Centers without sufficient capacity for downstream follow-up (advanced imaging or genetics) may create a bottleneck.
Sites using mammography workflows heavily dependent on synthetic 2D as the primary standard view, given Clairity’s documented limitation.
Organizations requiring published security certifications as gating criteria unless Clairity can provide them under NDA.

Vendor-acknowledged / publicly documented constraints

Image type support limitations: Clairity notes it analyzes FFDM / directly acquired 2D from specific systems and does not analyze synthetic 2D images (important for tomosynthesis-heavy workflows).

Roadmap / future products mentioned publicly

Press materials mention development of:
- Clairity Breast 3D
- Clairity Heart (cardiovascular risk prediction from routine imaging)

Scale limitations

Not publicly documented (throughput, latency, max studies/day, downtime SLAs, etc.). Buyers should request performance SLAs and reference architectures.

Security/compliance gaps

As noted, security certifications not publicly documented in accessible sources.

02Why they buy

Differentiators supported by available evidence

FDA De Novo authorization for an image-based AI platform intended to provide 5-year breast cancer risk prediction from screening mammography.
Vendor states the model derives additional imaging features beyond standard clinical inputs and emphasizes goals related to equitable risk assessment.

Where competitors may have advantages

Broader suite maturity: iCAD and other established imaging AI vendors may offer more mature deployment playbooks, broader device coverage, and packaged offerings.
Workflow depth: MagView and similar platforms may provide deeper operational tooling for letters, tracking, compliance, and risk clinic operations.

03Field reports

Key limitation: scarce review-platform coverage

Gartner Peer Insights: access attempt was blocked by robots.txt during collection; no accessible Clairity listing was retrieved.
G2 / TrustRadius / Capterra: searches did not surface a Clairity Breast listing with end-user reviews.

What we can use instead

Because formal review coverage is missing, feedback is currently inferred mostly from:

Early deployment news coverage
Vendor statements
Regulatory documents describing intended use and limitations
Community discussion is sparse and often not about the medical product

Vendor/press statements (neutral summary)

Vendor and partner communications describe applying predictive analytics to screening mammography and note early clinical rollout milestones.
Local reporting notes the product may identify risk not captured by genetic testing, while also reporting limited or unclear insurance coverage.

Negative/critical signals (where available)

Because validated end-user review quotes are not available, the main criticisms are structural adoption risks surfaced in reporting and regulatory framing:

Coverage and payment uncertainty: reporting indicates the technology is not widely covered by insurance yet, which is a practical adoption barrier (providers may hesitate without reimbursement clarity; patients may face out-of-pocket costs).
Intended-use limits: FDA documentation emphasizes it’s not a diagnostic/detection tool; organizations must avoid over-relying on the score in ways the device is not authorized for.

Why customers may choose Clairity vs alternatives (inferred)

A multi-year prediction horizon based on mammography alone (differentiator vs alternatives oriented to shorter horizons or requiring non-imaging data).
FDA De Novo authorization for this indication (provides regulatory context compared with non-cleared academic tools).
Workflow integration via the MagView ecosystem may reduce integration work for centers using that vendor.

Why some may not purchase / may delay (inferred)

Budget/reimbursement concerns.
Need for strong clinical governance and patient communication protocols.
Concerns about bias, generalizability, and medico-legal exposure if risk scores change management decisions.

Early deployment milestone (Beth Israel Deaconess Medical Center)

News coverage reported a rollout at Beth Israel Deaconess Medical Center in early 2026, describing the tool and reiterating insurance coverage is not in place.

Critical evaluation:

This is not a quantified ROI case study (no published metrics such as increased detection rates, stage shift, or reduced interval cancers). It is primarily a deployment announcement.

Vendor-published clinical validation narrative

Company materials and clinical summaries describe training/validation cohorts (e.g., very large mammography datasets used in development and large U.S. validation cohorts with multi-year outcomes).

Critical evaluation:

These are largely vendor-reported summaries. Buyers should request:
- full peer-reviewed validation publications
- site-level subgroup performance (race/ethnicity, age, density, equipment vendors)
- calibration plots and decision-curve analyses
- clinical utility evidence (changes in management and outcomes)

04Best fit

Best-fit organizations

Health systems / imaging networks with:
- established breast imaging volume (screening mammography at scale)
- active high-risk screening programs (MRI capacity, genetics referral pathways)
- robust radiology IT integration capabilities

Indicative size range (practical, not strict):

Multi-site imaging groups or hospitals with high annual screening volumes where predictive risk stratification could materially reshape downstream pathways.

Strongest roles/personas

Decision makers: VP women’s health, radiology chair, breast imaging director, population health leadership, CFO/finance (reimbursement).
End users: breast radiologists, nurse navigators, genetic counselors, scheduling teams.

Key pain points addressed

Under-identification of elevated risk when risk is not genetic and when clinical risk model inputs are incomplete.
Desire to move from a uniform annual screening approach to risk-stratified pathways.

05The pitch

What the product does (objective value proposition)

Key product claims and scope (per vendor and FDA materials):

Produces a calibrated 5-year risk score from screening mammography images; explicitly not intended to diagnose or detect breast cancer.
The healthcare-provider page indicates modality/device constraints (e.g., supports FFDM / directly acquired 2D and does not analyze synthetic 2D images; mentions compatibility with Hologic Lorad Selenia and Selenia Dimensions systems).

Target market and positioning

Primary buyers/users appear to be:

U.S. health systems, breast imaging centers, radiology groups (especially those operating risk clinics / high-risk screening programs).
Stakeholders: radiologists, breast imagers, breast surgeons, high-risk program coordinators, and women’s health program leadership.

Vendor communications describe the product as a predictive capability integrated with routine mammography workflows and as a tool intended to broaden identification of elevated risk beyond genetics-based approaches.

Get a comprehensive analysis of Clairity, Inc. including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →